Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
$28.97
$29.57
$25.80
$32.25
$10.31B0.4639 shsN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$58.07
+0.2%
$57.44
$52.93
$93.04
$11.15B0.181.94 million shs1.41 million shs
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$12.31
-0.4%
$10.44
$6.60
$14.11
$2.91B1.367,903 shs12,166 shs
QIAGEN N.V. stock logo
QGEN
QIAGEN
$49.13
-0.1%
$48.53
$37.63
$51.88
$10.92B0.641.37 million shs695,538 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
0.00%0.00%-2.75%-5.02%+20.33%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
+1.13%-0.58%+2.48%-0.09%-38.24%
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
+0.98%-0.96%+28.38%+45.29%-2.29%
QIAGEN N.V. stock logo
QGEN
QIAGEN
+0.13%-0.06%+2.42%+16.30%+7.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
N/AN/AN/AN/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
4.9964 of 5 stars
4.45.00.03.33.01.74.4
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/AN/AN/AN/AN/AN/AN/AN/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
3.7612 of 5 stars
1.12.01.74.53.41.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
4.00
Strong BuyN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.72
Moderate Buy$93.1760.45% Upside
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
0.00
N/AN/AN/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
2.27
Hold$49.691.12% Upside

Current Analyst Ratings Breakdown

Latest BVNRY, BMRN, QGEN, and BIOVF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$48.00 ➝ $50.00
8/6/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$101.00 ➝ $106.00
8/5/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$94.00
8/5/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$113.00 ➝ $114.00
7/22/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$97.00 ➝ $96.00
7/15/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$95.00
7/14/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$108.00 ➝ $113.00
7/3/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$97.00
6/26/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $53.00
(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
$2.46B4.19$2.05 per share14.12$11.36 per share2.55
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$2.85B3.91$3.29 per share17.66$31.39 per share1.85
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$829.12M3.51$1.02 per share12.08$6.99 per share1.76
QIAGEN N.V. stock logo
QGEN
QIAGEN
$1.98B5.52$3.20 per share15.35$15.77 per share3.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
$367.52M$1.1924.34N/A16.05%11.67%6.34%10/23/2025 (Estimated)
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$426.86M$3.3717.2313.320.7421.45%12.59%10.13%11/4/2025 (Estimated)
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$143.26M$0.8015.3811.72N/A21.11%11.89%9.32%8/28/2025 (Estimated)
QIAGEN N.V. stock logo
QGEN
QIAGEN
$83.59M$1.6929.0319.972.5818.30%14.77%8.87%11/5/2025 (Estimated)

Latest BVNRY, BMRN, QGEN, and BIOVF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.60$0.60N/A$0.44$523.97 million$533.54 million
7/16/2025Q2 2025
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
$0.18$0.24+$0.06$0.19$644.68 million$649.61 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/AN/AN/AN/AN/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.51%N/A14.79%N/A

Latest BVNRY, BMRN, QGEN, and BIOVF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.52%7/2/20257/3/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
0.22
1.00
0.66
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.10
5.56
3.60
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
2.81
1.44
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.25
1.61
1.35

Institutional Ownership

CompanyInstitutional Ownership
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
N/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
70.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
1,937356.00 millionN/ANot Optionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,040192.01 million190.38 millionOptionable
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
1,611236.57 millionN/ANot Optionable
QIAGEN N.V. stock logo
QGEN
QIAGEN
5,765222.29 million202.29 millionOptionable

Recent News About These Companies

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis
Qiagen Executive Sells Significant Shareholding
Nuveen LLC Invests $44.08 Million in Qiagen N.V. (NYSE:QGEN)
Kepler Capital Remains a Hold on Qiagen (QGEN)
QIAGEN (NYSE:QGEN) Downgraded by Wall Street Zen to "Buy"
Qiagen (NYSE:QGEN) Cut to Buy at Wall Street Zen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Swedish Orphan Biovitrum stock logo

Swedish Orphan Biovitrum OTCMKTS:BIOVF

$28.97 0.00 (0.00%)
As of 08/19/2025

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$58.07 +0.11 (+0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$58.04 -0.03 (-0.05%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Bavarian Nordic stock logo

Bavarian Nordic OTCMKTS:BVNRY

$12.31 -0.05 (-0.36%)
As of 11:38 AM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

QIAGEN stock logo

QIAGEN NYSE:QGEN

$49.13 -0.07 (-0.13%)
Closing price 03:59 PM Eastern
Extended Trading
$49.14 +0.00 (+0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.